CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Video

Natalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.

Natalie S. Grover, MD, assistant professor at the University of North Carolina Chapel Hill, discusses the potential role of CD30-specific chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory Hodgkin lymphoma.

While the majority of patients treated in the first-line setting will do well, there is still a portion of patients that have refractory disease, Grover says. While there are great treatment options available, including brentuximab vedotin (Adcetris), and checkpoint inhibitors, these are still not curative.

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content